Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

C 2402/JW 0104

Next Previous
Drug Profile

C 2402/JW 0104

Alternative Names: C 2402 + JW 0104; C-2402/JW-0104; JW 0104 + C 2402

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator JW Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dyslipidaemias; Hypertension

Most Recent Events

  • 22 Apr 2025 JW Pharmaceutical completes a phase-I clinical trials in Dyslipidaemias and Hypertension (In volunteers) in South Korea (PO) (NCT06754943)
  • 17 Jan 2025 Phase-I clinical trials in Dyslipidaemias (In volunteers) in South Korea (PO) (NCT06754943)
  • 17 Jan 2025 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO) (NCT06754943)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top